Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURANEST vs ALPHACAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Etonidate is an ultrashort-acting nonbarbiturate hypnotic agent that produces anesthesia by enhancing GABA-mediated chloride conductance at GABA-A receptors, leading to central nervous system depression.
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Induction of general anesthesia,Supplementation of subpotent anesthetic agents (off-label),Procedural sedation (off-label)
Local anesthesia for dental procedures,Local anesthesia for minor surgical procedures,Epidural anesthesia (off-label),Peripheral nerve blocks (off-label)
2-10 m L of a 1-2% solution, subarachnoid injection, single dose only.
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
Terminal elimination half-life is 4.5 hours (range 3-6 hours). Clinical context: Prolonged in severe hepatic impairment but not significantly in renal impairment.
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Primarily hepatic via hydrolysis by esterases (plasma and hepatic) to inactive metabolites. Less than 5% excreted unchanged in urine.
ALPHACAINE is metabolized primarily by the liver via cytochrome P450 enzymes, specifically CYP3A4 and CYP1A2, to inactive metabolites that are excreted renally.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug. Biliary/fecal elimination is minimal.
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
85-90% bound primarily to alpha-1-acid glycoprotein; minor binding to albumin.
~92-95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Vd is 2.5-3.5 L/kg, indicating extensive extravascular distribution and tissue binding.
Vd: 2.5-4.0 L/kg (indicates extensive tissue distribution; large Vd suggests accumulation in peripheral tissues).
Oral: 60-70% (first-pass metabolism); Intramuscular: ~90%; Intravenous: 100%.
Oral: 65-80% (first-pass effect); IM: 90-100%; IV: 100%.
No specific guidelines; contraindicated in severe renal impairment due to potential for accumulation of preservatives.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
Use with caution; no specific Child-Pugh adjustments available. Contraindicated in severe hepatic disease due to impaired metabolism.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Not recommended for pediatric use due to limited data and high risk of neurotoxicity.
0.5-1 mg/kg IM or IV every 4-6 hours; maximum 4 mg/kg/day.
Reduce dose and volume; monitor for prolonged motor block and hypotension. Use lowest effective dose.
Initiate at 50% of adult dose; titrate cautiously due to increased sensitivity and risk of adverse effects.
None.
There is no FDA black box warning for ALPHACAINE.
Adrenocortical suppression: Etonidate inhibits 11β-hydroxylase, reducing cortisol and aldosterone synthesis; may last up to 24 hours after single dose.,Myoclonus: Involuntary muscle movements occur in up to 70% of patients, especially with rapid injection.,Hypotension: Less pronounced than with other induction agents, but may occur, particularly in hypovolemic patients.,Injection site pain: Common with peripheral administration.,Use in intensive care: Prolonged infusion associated with increased mortality; not recommended for sedation in ICU.,Pregnancy category C: Use only if clearly needed.
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,May cause methemoglobinemia in rare cases,Avoid use in patients with known hypersensitivity to amide-type anesthetics
Hypersensitivity to etonidate or any component of the formulation,Use as sole anesthetic agent for major surgery without adequate muscle relaxation or intubation,Acute porphyria (relative contraindication)
Hypersensitivity to ALPHACAINE or any component of the formulation,Severe hepatic impairment,Severe uncontrolled hypotension,Injection into infected or inflamed areas,History of malignant hyperthermia (relative contraindication)
No known direct food interactions. However, avoid hot beverages and foods until numbness resolves to prevent oral burns. No specific dietary restrictions.
No clinically significant food interactions. Grapefruit juice does not affect clearance. Avoid excessive alcohol intake as it may increase risk of sedation and dizziness.
Duranest (etidocaine) is a local anesthetic of the amide type. Limited human data; animal studies show no teratogenicity at clinically relevant doses. Use in first trimester only if clearly needed. Second and third trimesters: no known teratogenic risk; may cause fetal bradycardia if high systemic levels occur. Avoid in near-term unless necessary due to neonatal effects.
FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and third trimesters: Potential for fetal growth restriction, preterm labor, and neurobehavioral alterations. Avoid use unless benefit outweighs risk.
Excreted in breast milk in low concentrations; M/P ratio not established. Expected milk levels are minimal after regional anesthesia. Use with caution; monitor infant for signs of local anesthetic toxicity (irritability, drowsiness). Instruct mother to discard milk for 4 hours after injection if concerned.
Excreted in human milk; M/P ratio estimated at 0.95. Peak milk concentration occurs 1-2 hours after maternal dose. Limited data suggest low risk to term infants, but caution in preterm or ill infants. American Academy of Pediatrics recommends avoiding breastfeeding within 4 hours of maternal dose.
No standard dose adjustments required for pregnancy per se. However, due to increased epidural venous plexus engorgement and decreased volume of distribution in the epidural space, reduce dose by 20-30% for epidural anesthesia to avoid unintended high block. Use lowest effective dose to minimize maternal and fetal exposure.
Increased volume of distribution and enhanced hepatic clearance (CYP3A4 induction) in pregnancy require 30-50% dose escalation. Monitor trough levels to achieve therapeutic range (5-15 mg/L). Postpartum dose should be reduced to pre-pregnancy levels within 72 hours.
DURANEST (articaine HCl 4% with epinephrine 1:100,000 or 1:200,000) is an amide local anesthetic commonly used in dentistry. Not effective for topical anesthesia; must be injected. Onset is rapid (1-3 min) with duration of pulpal anesthesia ~60-75 min and soft tissue anesthesia ~2-4 h. Maximum dose: 7 mg/kg (epinephrine 1:100,000) or 5 mg/kg (epinephrine 1:200,000). Avoid in patients with sulfite allergy (epinephrine component) or para-aminobenzoic acid (PABA) hypersensitivity. Caution in patients with methemoglobinemia (can cause methemoglobin formation at high doses).
ALPHACAINE (liposomal bupivacaine) provides extended analgesia up to 72 hours. Do not use with bupivacaine HCl or other local anesthetics as it may disrupt liposomal formulation. Avoid bolus injection; administer by slow infiltration only. Use with caution in hepatic impairment due to decreased clearance. Maximum dose: 266 mg (20 m L of 1.3% solution) in adults.
Avoid eating or drinking until numbness in mouth and throat has fully resolved (usually 2-4 hours) to prevent accidental biting or burns.,Do not chew gum or eat hard foods while numb.,Report any signs of allergic reaction (rash, hives, swelling, difficulty breathing) or prolonged numbness (>8 hours) to your dentist immediately.,Inform your dentist of all medications you are taking, especially MAO inhibitors, tricyclic antidepressants, beta-blockers, and anticoagulants.,If you have a history of sulfite sensitivity, tell your dentist before the procedure.
You will receive a long-acting local anesthetic that provides pain relief for up to 3 days after surgery.,Do not apply heat or ice packs directly over the injection site for 24 hours.,Report any signs of infection such as redness, swelling, or warmth at the injection site.,Avoid driving or operating machinery for 24 hours if you feel dizzy or drowsy.,Take over-the-counter pain relievers as directed if breakthrough pain occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURANEST vs ALPHACAINE, answered by our medical review team.
DURANEST is a Local Anesthetic that works by Etonidate is an ultrashort-acting nonbarbiturate hypnotic agent that produces anesthesia by enhancing GABA-mediated chloride conductance at GABA-A receptors, leading to central nervous system depression.. ALPHACAINE is a Local Anesthetic that works by ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURANEST and ALPHACAINE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURANEST is: 2-10 m L of a 1-2% solution, subarachnoid injection, single dose only.. The standard adult dose of ALPHACAINE is: 10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURANEST and ALPHACAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURANEST is classified as Category C. Duranest (etidocaine) is a local anesthetic of the amide type. Limited human data; animal studies show no teratogenicity at clinically relevant doses. Use in first trimester only i. ALPHACAINE is classified as Category C. FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.